Marijuana use in the United States has increased in recent years, with many states having legalized its medical use. Now, researchers at the Salk Institute have discovered that its active compound tetrahydrocannabinol (THC) may eliminate amyloid beta protein.

According to Salk Institute Professor David Schubert, “Although other studies have offered evidence that cannabinoids might be neuroprotective against the symptoms of Alzheimer’s, we believe our study is the first to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells.”

These laboratory findings are promising, but extensive clinical trials will be necessary to determine the actual effectiveness of the drug in patients with symptoms, as well as those at risk.